id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-324060-vvexfg1c	Bogdanos, Dimitrios P.	When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?	2020-03-31		.txt	text/plain	2725	163	52	The current use of chloroquine and/or hydroxychloroquine, a drug currently used to treat autoimmune rheumatic diseases, in treating severe acute respiratory syndrome caused by coronavirus 2 (SARSCoV-2) or COVID-19-infected patients with pneumonia is a matter of intense consideration. There is no certainty that chloroquine and/or hydroxychloroquine is efficacious for the severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) or COVID-19-infected patients with pneumonia, especially immunocompromised patients. Based on the Italian and Spanish experience, we anticipate that we will have a shortage of ventilators and intensive care unit beds if we have many severe COVID-19-infected cases in Greece (https://www.reuters.com/ article/us-health-coronavirus-draegerwerk-ventil/germany-italy-rush-to-buy-life-saving-ventilators-as-manufacturers-warn-of-shortages-idUSKBN210362). In China alone, at least 23 clinical trials investigate the efficacy and safety of chloroquine or hydroxychloroquine for the treatment of COVID-19-associated pneumonia. The expert panel of the National Public Health Authority has very recently (26 March 2020) revised the therapeutic protocol/algorithm for the treatment of symptomatic COVID-19 patients, which includes hydroxychloroquine/ chloroquine.	./cache/cord-324060-vvexfg1c.txt	./txt/cord-324060-vvexfg1c.txt